CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
JP2919890B2
(ja)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
WO1991003489A1
(en)
|
1989-09-08 |
1991-03-21 |
The Johns Hopkins University |
Structural alterations of the egf receptor gene in human gliomas
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
CA2116774C
(en)
|
1991-09-19 |
2003-11-11 |
Paul J. Carter |
Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2129663C
(en)
|
1992-02-06 |
2005-07-05 |
James S. Huston |
Biosynthetic binding protein for cancer marker
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
ATE207366T1
(de)
|
1993-12-24 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
EP0831880A4
(en)
|
1995-06-07 |
2004-12-01 |
Imclone Systems Inc |
ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
DK0836605T3
(da)
|
1995-07-06 |
2002-05-13 |
Novartis Ag |
Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
EP0892789B2
(en)
|
1996-04-12 |
2009-11-18 |
Warner-Lambert Company LLC |
Irreversible inhibitors of tyrosine kinases
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
DE69815340T2
(de)
|
1997-05-06 |
2004-05-06 |
Wyeth Holdings Corp. |
Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
DE69830315T2
(de)
|
1997-06-24 |
2006-02-02 |
Genentech Inc., San Francisco |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
CA2306155A1
(en)
|
1997-11-06 |
1999-05-20 |
Philip Frost |
Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
DK1034298T3
(da)
|
1997-12-05 |
2012-01-30 |
Scripps Research Inst |
Humanisering af murint antistof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
ATE458007T1
(de)
|
1998-04-20 |
2010-03-15 |
Glycart Biotechnology Ag |
Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
|
HUP0104211A3
(en)
|
1998-11-19 |
2003-01-28 |
Warner Lambert Co |
N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
DE60022369T2
(de)
|
1999-10-04 |
2006-05-18 |
Medicago Inc., Sainte Foy |
Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
US20030180714A1
(en)
|
1999-12-15 |
2003-09-25 |
Genentech, Inc. |
Shotgun scanning
|
ATE344801T1
(de)
|
1999-12-29 |
2006-11-15 |
Immunogen Inc |
Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
HU231090B1
(hu)
|
2000-10-06 |
2020-07-28 |
Kyowa Kirin Co., Ltd. |
Antitest-kompozíciót termelő sejt
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7041870B2
(en)
|
2000-11-30 |
2006-05-09 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
CA2838062C
(en)
|
2001-08-03 |
2015-12-22 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
WO2003084570A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
EP1513879B1
(en)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
EP1705251A4
(en)
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
PL2157192T3
(pl)
|
2003-10-10 |
2014-01-31 |
Deutsches Krebsforsch |
Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
|
WO2005044859A2
(en)
|
2003-11-05 |
2005-05-19 |
Glycart Biotechnology Ag |
Cd20 antibodies with increased fc receptor binding affinity and effector function
|
SI1725249T1
(sl)
|
2003-11-06 |
2014-04-30 |
Seattle Genetics, Inc. |
Spojine monometilvalina, sposobne konjugacije na ligande
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
AU2005230848B9
(en)
|
2004-03-31 |
2011-06-02 |
Genentech, Inc. |
Humanized anti-TGF-beta antibodies
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
ES2403055T3
(es)
|
2004-04-13 |
2013-05-13 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-P-selectina
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
WO2006034488A2
(en)
|
2004-09-23 |
2006-03-30 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
US20070237764A1
(en)
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
CA2651567A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
US8088374B2
(en)
|
2006-10-20 |
2012-01-03 |
Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts |
Methods for inhibition of angiogenesis and vasculogenesis via rspondin antagonists
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
EP2977060A1
(en)
*
|
2009-12-23 |
2016-01-27 |
Deutsches Krebsforschungszentrum |
Receptors of rspo2 and rspo3
|
US8802097B2
(en)
*
|
2011-07-15 |
2014-08-12 |
Oncomed Pharmaceuticals, Inc. |
Anti-RSPO1 antibodies
|
US9611330B2
(en)
|
2011-09-08 |
2017-04-04 |
The Regents Of The University Of California |
Compositions and methods for cancer and cancer stem cell detection and elimination
|
US9296826B2
(en)
|
2011-10-14 |
2016-03-29 |
Novartis Ag |
Antibodies and methods for WNT pathway-related diseases
|
US10010565B2
(en)
*
|
2011-12-14 |
2018-07-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Stimulation of ovarian follicle development and oocyte maturation
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
WO2014012007A2
(en)
*
|
2012-07-13 |
2014-01-16 |
Oncomed Pharmaceuticals, Inc. |
Rspo3 binding agents and uses thereof
|